Literature DB >> 21974951

Synthesis and anti-HIV-1 activity of 4-substituted-7-(2'-deoxy-2'-fluoro-4'-azido-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine analogues.

Xiaohe Guo1, Yujiang Li, Le Tao, Qiang Wang, Shuyang Wang, Weidong Hu, Zhenliang Pan, Qinghua Yang, Yanmei Cui, Zhaopeng Ge, Lihong Dong, Xuejun Yu, Haoyun An, Chuanjun Song, Junbiao Chang.   

Abstract

Three novel 4-subsituted-7-(2'-deoxy-2'-fluoro-4'-azido-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine analogues were designed, synthesized, and tested for their anti-HIV-1 activity. Initial biological studies indicated that among these pyrrolo[2,3-d]pyrimidine ribonucleoside analogues, 4-amino-7-(2'-deoxy-2'-fluoro-4'-azido-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine 10 exhibited the most potent anti-HIV-1 activity (EC(50)=0.5±0.3 μM), while 4-hydroxy-7-(2'-deoxy-2'-fluoro-4'-azido-β-D-ribofuranosyl)pyrrolo[2,3-d] pyrimidine 9 and 4-amino-5-fluoro-7-(2'-deoxy-2'-fluoro-4'-azido-β-D-ribofuranosyl)pyrrolo[2,3-d] pyrimidine 11 showed moderate activity (EC(50)=13±8 and 5.4±0.3 μM, respectively). The cytotoxicity of these compounds has also been assessed. No significant cytotoxicities were found for any of these compounds with concentrations up to 25 μM.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21974951     DOI: 10.1016/j.bmcl.2011.09.040

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

Review 1.  Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides.

Authors:  Pavla Perlíková; Michal Hocek
Journal:  Med Res Rev       Date:  2017-08-23       Impact factor: 12.944

2.  Versatile synthesis and biological evaluation of novel 3'-fluorinated purine nucleosides.

Authors:  Hang Ren; Haoyun An; Paul J Hatala; William C Stevens; Jingchao Tao; Baicheng He
Journal:  Beilstein J Org Chem       Date:  2015-12-09       Impact factor: 2.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.